该文通过葡聚糖硫酸钠(dextran sulfate sodium,DSS)诱导的结肠炎小鼠模型,评价2株鼠李糖乳杆菌对小鼠结肠炎的缓解效果并探究其作用机制。结果显示,鼠李糖乳杆菌FZJTZ46L6对DSS引起的小鼠结肠炎具有显著的缓解作用,且效果优于FNMGEL5-1。FZJTZ46L6能够显著缓解DSS引起的小鼠体重下降,改善粪便性状和便血情况,且显著改善结肠黏膜损伤和炎症产生。而FNMGEL5-1虽然在一定程度上缓解了DSS引起的疾病症状,但是对于结肠炎症浸润和病理损伤没有改善作用。与模型组相比,鼠李糖乳杆菌FZJTZ46L6干预后显著提高结肠紧密连接相关蛋白基因转录水平,降低促炎因子TNF-α、IL-1β、IL-6和IFN-γ含量,显著增加小鼠粪便中短链脂肪酸含量,显著提高丙酸和丁酸产生菌属Coprococcus丰度并增加肠道菌群多样性。
In this study, DSS-induced colitis mice were used to investigate the effects of two Lactobacillus rhamnosus strains on disease and their potential mechanisms. C57BL/6J mice with colitis induced by 25 g/L DSS were administered with L. rhamnosus strains for 28 d. The results showed that L. rhamnosus FZJTZ46L6 alleviated DSS-induced colitis significantly and more effectively than that by FNMGEL5-1. L. rhamnosus FZJTZ46L6 alleviated the body weight loss caused by DSS, improved stool consistency and relieved bloody stool, and significantly improved the colonic mucosal damage in mice. Although FNMGEL5-1 alleviated the symptoms of diseases caused by DSS, it showed no effect on colonic inflammation and pathological damage. In addition, compared with the model group, L. rhamnosus FZJTZ46L6 significantly increased the transcription level of tight junction proteins in colon and reduced pro-inflammatory cytokines such as TNF-α、IL-1β、IL-6 and IFN-γ in colon. Besides, the content of short-chain fatty acids in the feces of mice was also increased significantly. The abundance of genera Coprococcus, the propionate and butyrate-producing bacteria, were elevated together with the diversity of gut microbiota.
[1] ABRAHAM C, CHO J H. Inflammatory bowel disease[J]. The New England Journal of Medicine, 2009, 361(21): 2 066-2 078.
[2] 王苗, 曲波, 李惠, 等. 炎症性肠病的治疗新进展[J]. 胃肠病学和肝病学杂志, 2016,25(7):736-738.
[3] MATSUOKA K, KANAI T. The gut microbiota and inflammatory bowel disease[J]. Seminars in Immunopathology, 2015, 37(1): 47-55.
[4] TILG H, MOSCHEN A R. Microbiota and diabetes: An evolving relationship[J]. Gut, 2014, 63(9):1 513-1 521.
[5] TIAN P, ZOU R, SONG L, et al. Ingestion of Bifidobacterium longum subspecies infantis strain CCFM687 regulated emotional behavior and the central BDNF pathway in chronic stress-induced depressive mice through reshaping the gut microbiota[J]. Food & Function, 2019, 10(11): 7 588-7 598.
[6] GOPHNA U, SOMMERFELD K, GOPHNA S, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis[J]. Journal of Clinical Microbiology, 2006, 44(11): 4 136-4 141.
[7] 王俊通. 产共轭亚油酸乳酸菌对DSS诱导小鼠结肠炎的改善作用[D]. 无锡:江南大学,2016.
[8] FINEGOLD S M, SCOT E D, VIKTORIA G, et al. Pyrosequencing study of fecal microflora of autistic and control children[J]. Anaerobe, 2010,16(4): 444-453.
[9] ZELANTE T, IANNITTI R G, CUNHA C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via Interleukin-22[J]. Immunity, 2013,39(2): 372-385.
[10] ZHAO Y, CHEN F, WU W, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3[J]. Mucosal Immunology, 2018, 11(3): 752-762.
[11] JUNG-HA P, KOTANI T, KONNO T, et al. Promotion of Intestinal epithelial cell turnover by commensal bacteria: Role of short-chain fatty acids[J]. Plos One, 2016,11(5): e0 156 334.
[12] VENEGAS D P, LA FUENTE M d, LANDSKRON G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases[J]. Frontiers in Immunology, 2019, https://doi.org/10.3389/fimmu.2019.00 277.
[13] SHEN X, LIU L, PEEK R M, et al. Supplementation of p40, a Lactobacillus rhamnosus GG-derived protein, in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes[J]. Mucosal Immunology, 2018, 11(5):1 316-1 328.
[14] HERING N A, FROMM M, SCHULZKE J D. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics[J]. Journal of Physiology, 2012, 590(5):1 035-1 044.
[15] BERBERAT P O, YI A R, YAMASHITA K, et al. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis[J]. Inflammatory Bowel Diseases, 2005, 11(4): 350-359.
[16] 毛丙永. 功能性低聚糖对肠道细菌的影响及机制[D]. 无锡:江南大学, 2015.
[17] MAO B, LI D, ZHAO J, et al. Metagenomic insights into the effects of fructo-oligosaccharides (FOS) on the composition of fecal microbiota in mice[J]. Journal of Agricultural and Food Chemistry, 2015, 63(3): 856-863.
[18] ARATANI Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function[J]. Arch Biochem Biophys, 2018, 640:47-52.
[19] 禹晶. MPO、CD15、P53在大肠癌及溃疡性结肠炎中的表达及意义[D]. 佳木斯:佳木斯大学, 2008.
[20] 周泠, 刘卓志. 雷公藤多甙栓对溃疡性结肠炎大鼠SOD和MPO的影响[J]. 医学动物防制, 2006,22(6):403-405.
[21] JU S, GE Y, LI P, et al. Dietary quercetin ameliorates experimental colitis in mouse by remodeling the function of colonic macrophages via a heme oxygenase-1-dependent pathway[J]. Cell Cycle, 2018, 17(1): 53-63.
[22] YE M, JOOSSE M E, LIU L, et al. Deletion of IL-6 exacerbates colitis and induces systemic inflammation in IL-10-deficient mice[J/OL]. Journal of Crohn's & Colitis, 2019, https://doi.org/10.1093/ecco-jcc/jjz176.
[23] 王少鑫, 浦江, 刘超群, 等. 炎症因子TNF-α、IL-6和IL-4在溃疡性结肠炎中的表达及临床意义[J]. 胃肠病学和肝病学杂志, 2014,(1):104-106.
[24] ZENG H, UMAR S, RUST B, et al. Secondary bile acids and short chain fatty acids in the colon: A focus on colonic microbiome, cell proliferation, inflammation, and cancer[J]. International Journal of Molecular Sciences, 2019, 20(5):12-14.
[25] ZHUANG X, LI T, LI M, et al. Systematic review and meta-analysis: Short-chain fatty acid characterization in patients with inflammatory bowel disease[J]. Inflammatory Bowel Diseases, 2019, 25(11): 1 751-1 763.
[26] KOWALSKA-DUPLAGA K, GOSIEWSKI T, KAPUSTA P, et al. Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn's disease[J]. Sci Rep, 2019, 9(1): 18 880.
[27] RUSSO E, GIUDICI F, FIORINDI C, et al. Immunomodulating activity and therapeutic effects of short chain fatty acids and tryptophan post-biotics in inflammatory bowel disease[J]. Frontiers in Immunology, 2019, 10:2 754.
[28] LARABI A, BARNICH N, NGUYEN H T T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD[J]. Autophagy, 2020, 16(1): 38-51.
[29] KALLUS S J, BRANDT L J. The Intestinal microbiota and obesity[J]. Journal of Clinical Gastroenterology, 2012,46(1): 16-24.
[30] RAMOS G P, PAPADAKIS K A. Mechanisms of disease: Inflammatory bowel diseases[J]. Mayo Clinic Proceedings, 2019, 94(1): 155-165.
